BBIO BridgeBio Pharma, Inc. Common Stock
XNAS 68.15 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BBIO
$68.15
—
Key stats
$68.15
- 52-Week Range
- $56.74 – $93.42
- YTD
- -12.89%
- IV Rank (30D)
- 80.8
- Straddle Price
- $7.40
- P/C Vol Ratio
- 1.06
- Market Cap
- $13.4B
- Open
- $68.56
- Day Range
- $67.86 – $68.83
- Volume
- 2,059,135
- Prev Close
- $68.56
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.13% |
| Beta vs SPY | 1.07 |
| Cost of Equity (CAPM) | 11.00% (VRP-adj) |
| WACC | 10.29% |
| Volatility Risk Premium | +37.0pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.4B |
| Return on Equity (TTM) | 27.5% |
| Book / Price | -18.8% |
| Gross Margin (TTM) | 94.4% |
| FCF Margin (TTM) | -61.1% |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $71.38 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $66.50 |
| Bollinger Width / SMA20 | 11.2% (drives anchor stability) |
| Net Debt | $1.2B |
| Market Cap | $13B |
Peers used for multiples: GH, JNJ, LLY, MRK, NTRA, RVMD, UNH, VRTX
60-Day Conviction
64%
20-Day Fair Value
≈ by Nov 24, 2026
$68.53
α +0.6%
rank 39%
conviction
35%
40-Day Fair Value
≈ by Dec 23, 2026
$69.46
α +1.9%
rank 37%
conviction
62%
60-Day Fair Value
≈ by Jan 21, 2027
$69.56
α +2.1%
rank 33%
conviction
64%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.0× · 5 peers |
| Peer EV/EBITDA | n/a | 0% | median 25.2× · 5 peers |
| Peer P/B | n/a | 0% | median 8.7× · 7 peers |
| Peer P/S | $43.58 | 10% | median 10.8× · 7 peers |
| Market Anchor (SMA50) | $71.38 | 60% | stability 94% (BB-width) |
| Options Expected (B-L 30d) | $68.30 | 30% | 19 strikes · skew +0.51 |
As of 2026-10-26 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $13.4B
- Employees
- 839
- List Date
- 2019-06-27
- CIK
- 0001743881
- Next Earnings
- 2026-10-29 (After-Close)
- EPS Forecast
- ($0.60) (8 est.)
- Headquarters
- Palo Alto, CA
- Homepage
- https://www.bridgebio.com
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -10.81% | -42.48% | 29.43% | -15.23% | 21.31% | -1.23% | -3.17% |
| Feb | 23.07% | -27.84% | 16.89% | 2.52% | 12.47% | -15.03% | 2.01% |
| Mar | -14.34% | 21.41% | 46.86% | -13.22% | 4.73% | 13.37% | 9.80% |
| Apr | -5.80% | -26.08% | -12.37% | -14.54% | 16.17% | -4.49% | -7.85% |
| May | 6.92% | -18.88% | -4.32% | 3.63% | -10.81% | -3.35% | -4.47% |
| Jun | 0.98% | 37.78% | 22.86% | -12.59% | 21.77% | 13.95% | 14.12% |
| Jul | -15.97% | -12.70% | 101.79% | 2.98% | 10.50% | 6.83% | 15.57% |
| Aug | -4.24% | 24.11% | -12.72% | 6.38% | 9.27% | -4.21% | 3.10% |
| Sep | -7.44% | -2.74% | -13.77% | -11.41% | 3.88% | -14.07% | -7.59% |
| Oct | 3.44% | 0.58% | 2.48% | -5.60% | 17.13% | 1.85%* | 3.31% |
| Nov | -21.86% | -10.25% | 7.73% | 6.32% | 16.18% | -- | -0.38% |
| Dec | -57.84% | -17.44% | 30.48% | 3.16% | 6.56% | -- | -7.02% |
| Total | -75.73% | -67.30% | 400.72% | -41.34% | 227.90% | -10.37% | 72.31% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $66.57
SMA 50: $71.15
SMA 200: $72.87
Current: $68.15
EMA 12: $67.34
EMA 26: $67.94
MACD: -0.6037 | Signal: 0.6771
BEARISH
ADX (14): 19.69
RANGE
+DI: 17.08
−DI: 16.83
Momentum Oscillators
RSI (14): 50.50
NEUTRAL
Stoch %K: 83.85
Stoch %D: 82.00
Williams %R: -18.11
Volume & Volatility
BB Upper: $69.15
BB Lower: $64.00
NEUTRAL
OBV: 74,899,618
Vol SMA 20: 2,646,316
Vol ROC: 15.75%
ATR: $2.12
True Range: $0.97
HV 20: 26.8%
HV 30: 34.3%
HV 60: 30.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: BBIO
Executive Summary: BULLISH (Confidence Level: 8/10)
Key drivers:
- Positive news sentiment surrounding Acoramidis' efficacy and BridgeBio's rare-disease pipeline
- Technical indicators showing a bullish trend, with MACD signal line crossing above the MACD histogram
Primary risks:
- High volatility, with beta at 1.25 (vs SPY)
- Options market pricing $10.30 move by expiration, indicating potential for significant price swings
Investment thesis: BBIO is poised to continue its upward momentum driven by positive news and technical indicators, despite some near-term risks.
Recent news sentiment impact: Positive news headlines have contributed to the stock's recent gains, with Acoramidis' efficacy data and BridgeBio's pipeline progress sparking enthusiasm among investors.
Technical Analysis:
- Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Neutral
- Support/Resistance Levels: Upper Bollinger Band ($79.94), Middle Bollinger Band ($74.03)
- Momentum Signals:
- RSI interpretation: 42.26 (neutral) - no buy/sell signal
- MACD signal line crossing above the MACD histogram - bullish momentum
- Bollinger Bands position: neutral, with price touching the middle band
- Volume Analysis: Volume SMA 20: 2502239.26, On-Balance Volume (OBV): 47379335.49
News & Sentiment Analysis:
- Recent Headlines Summary: Positive news on Acoramidis' efficacy and BridgeBio's rare-disease pipeline
- Sentiment Assessment: Aggregate sentiment is positive, with a focus on the company's pipeline progress and therapeutic advancements
- Catalyst Identification: Upcoming FDA filing for BridgeBio's dwarfism treatment in 2026
- Market Narrative: News sentiment aligns with technical signals, highlighting the potential for continued upward momentum
Risk & Volatility Assessment:
- Beta Interpretation: High risk relative to market (beta >1.2)
- Volatility Regime: Current volatility is higher than historical levels
- Options Market Signals: IV rank: 0.0% (Low), put/call ratios: neutral, unusual activity: moderate
Market Context & Positioning:
- Sector Performance: BBIO outperforms the biotech sector and broader market
- Institutional Activity: Volume patterns suggest institutional interest in the stock
- Correlation Analysis: Stock moves relative to the market (R-squared interpretation): 0.33 - moderate correlation
Key Levels & Action Items:
- Critical Price Levels: Upper Bollinger Band ($79.94), Middle Bollinger Band ($74.03)
- Breakout/Breakdown Levels: Technical levels that could trigger significant moves include the upper and lower Bollinger Bands
- Time-Sensitive Catalysts: FDA filing for dwarfism treatment in 2026, BridgeBio's pipeline progress updates
- Risk Management: Stop-loss levels: $68.12 (lower Bollinger Band), position sizing considerations: moderate
Overall, BBIO presents a bullish case with strong technical indicators and positive news sentiment driving the stock's upward momentum. However, high volatility and options market pricing suggest potential for significant price swings. Investors should monitor key levels and catalysts while managing risk through stop-loss levels and position sizing considerations.
Generated
News
All BBIO news →
Earnings History
20 of 21 under expected move
Avg Expected Move
18.97%
Avg Actual Move
3.60%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-26 | After-Close | 13.79% | 1.74% | 0.13x | Within |
| 2021-05-14 | After-Close | 9.28% | 0.88% | 0.09x | Within |
| 2021-11-04 | After-Close | 4.86% | 3.79% | 0.78x | Within |
| 2022-02-24 | After-Close | 22.50% | 1.25% | 0.06x | Within |
| 2022-05-10 | After-Close | 127.11% | 13.88% | 0.11x | Within |
| 2022-08-04 | After-Close | 19.04% | 12.12% | 0.64x | Within |
| 2022-11-03 | After-Close | 21.81% | 0.20% | 0.01x | Within |
| 2023-02-23 | After-Close | 23.65% | 0.17% | 0.01x | Within |
| 2023-05-04 | After-Close | 14.67% | 1.33% | 0.09x | Within |
| 2023-08-03 | After-Close | 11.09% | 2.65% | 0.24x | Within |
| 2023-11-02 | After-Close | 5.20% | 7.10% | 1.37x | Exceeded |
| 2024-02-22 | After-Close | 14.29% | 1.19% | 0.08x | Within |
| 2024-05-02 | After-Close | 10.63% | 0.32% | 0.03x | Within |
| 2024-08-01 | After-Close | 15.66% | 0.00% | 0.00x | Within |
| 2024-11-12 | Pre-Market | 9.48% | 5.74% | 0.61x | Within |
| 2025-02-20 | Pre-Market | 9.30% | 1.42% | 0.15x | Within |
| 2025-04-29 | After-Close | 12.29% | 5.33% | 0.43x | Within |
| 2025-08-05 | After-Close | 18.70% | 8.94% | 0.48x | Within |
| 2025-10-29 | After-Close | 13.88% | 4.88% | 0.35x | Within |
| 2026-02-24 | After-Close | 12.37% | 2.59% | 0.21x | Within |
| 2026-05-07 | After-Close | 8.78% | 0.09% | 0.01x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
BBIO Options Activity & IV Rank
BBIO IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 51.3%
7-DTE IV: —
Expected Move: $7.40
7-DTE Move: $7.40
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 173
Put Volume: 184
P/C Volume: 1.064
NEUTRAL
Call OI: 3,978
Put OI: 2,121
P/C OI: 0.533
Total OI: 6,099
ATM Options Pricing
ATM Call: $4.25
ATM Put: $3.15
Call %: 6.2%
Put %: 4.6%
Chain Summary
Chain Volume: 4,033
Chain OI: 34,853
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 12th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
12%
vs own history
GEX tilt
-0.20
OI-weighted, today
Vanna tilt
+0.46
δ-sensitivity to IV
Charm tilt
-0.34
δ-decay vs time
Vanna tilt +0.46: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.34: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 39 ATM contracts, 14k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
68%
+10.1
pts
EXTREME
as of Oct 26 · ATM 51.8% / Wing 61.9%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)80.8HighOct 26
Straddle Price (30 DTE)$7.40Oct 26
Beta Analysis
Risk Metrics
Beta: 1.0935
Alpha: 19.38%
Correlation: 0.2968
R-Squared: 8.8%
Stock Volatility: 47.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own BBIO
7 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Viking Global Hedge fund Andreas Halvorsen | $741.0M | #15 of 90 | -16.0% | 13F | |
| Citadel Hedge fund Ken Griffin | $328.8M | #92 of 6285 | +932.2% | 13F | |
| Point72 Hedge fund Steve Cohen | $113.6M | #148 of 1945 | new | 13F | |
| Millennium Management Hedge fund Izzy Englander | $67.7M | #479 of 3716 | -29.7% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $63.8M | #257 of 3138 | +134.3% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $33.4M | #123 of 997 | +72.7% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $3.4M | #1140 of 4729 | -15.5% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
BBIO Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 194,005,810 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
24 filers$1.66B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | UBS Group AG Custodian | $575.51M | 34.74% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $464.81M | 28.06% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $390.30M | 23.56% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $42.56M | 2.57% | 2026-06-30 |
| 5 | NOMURA HOLDINGS INC | $39.62M | 2.39% | 2026-06-30 |
| 6 | Caption Management, LLC | $35.45M | 2.14% | 2026-06-30 |
| 7 | Millennium Management LLC Custodian | $27.14M | 1.64% | 2026-06-30 |
| 8 | Troluce Capital Advisors LLC | $14.90M | 0.90% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $12.08M | 0.73% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $11.54M | 0.70% | 2026-06-30 |
| 11 | Citigroup Inc. Custodian | $8.94M | 0.54% | 2026-06-30 |
| 12 | Goldman Sachs Group Inc Custodian | $7.97M | 0.48% | 2026-06-30 |
| 13 | SIG BROKERAGE, LP | $5.96M | 0.36% | 2026-06-30 |
| 14 | TUDOR INVESTMENT CORP ET AL | $4.84M | 0.29% | 2026-06-30 |
| 15 | Wolverine Trading, LLC Custodian | $4.43M | 0.27% | 2025-09-30 |
| 16 | Simplex Trading, LLC Custodian | $2.72M | 0.16% | 2026-06-30 |
| 17 | CSS LLC/IL | $1.94M | 0.12% | 2026-06-30 |
| 18 | Walleye Capital LLC | $1.92M | 0.12% | 2026-06-30 |
| 19 | Two Sigma Investments, LP Custodian | $1.49M | 0.09% | 2026-06-30 |
| 20 | BOOTHBAY FUND MANAGEMENT, LLC | $1.09M | 0.07% | 2026-06-30 |
| 21 | Point72 Asset Management, L.P. | $1.04M | 0.06% | 2026-06-30 |
| 22 | Walleye Trading LLC | $283.02K | 0.02% | 2026-06-30 |
| 23 | TOCQUEVILLE ASSET MANAGEMENT L.P. | $148.96K | <0.01% | 2026-06-30 |
| 24 | RITHOLTZ WEALTH MANAGEMENT | $44.69K | <0.01% | 2026-06-30 |
18 filers$283.55M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $146.80M | 51.77% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $41.89M | 14.77% | 2026-06-30 |
| 3 | Citigroup Inc. Custodian | $29.20M | 10.30% | 2026-06-30 |
| 4 | Caption Management, LLC | $14.90M | 5.25% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $8.77M | 3.09% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $7.57M | 2.67% | 2026-06-30 |
| 7 | Simplex Trading, LLC Custodian | $5.47M | 1.93% | 2026-06-30 |
| 8 | GROUP ONE TRADING LLC Custodian | $4.61M | 1.63% | 2026-06-30 |
| 9 | D. E. Shaw & Co., Inc. Custodian | $4.60M | 1.62% | 2026-06-30 |
| 10 | UBS Group AG Custodian | $4.28M | 1.51% | 2026-06-30 |
| 11 | LAZARD ASSET MANAGEMENT LLC | $3.58M | 1.26% | 2026-06-30 |
| 12 | Barclays PLC Custodian | $3.04M | 1.07% | 2026-06-30 |
| 13 | Wolverine Trading, LLC Custodian | $2.87M | 1.01% | 2025-09-30 |
| 14 | WOLVERINE ASSET MANAGEMENT LLC | $2.22M | 0.78% | 2026-06-30 |
| 15 | Two Sigma Investments, LP Custodian | $1.95M | 0.69% | 2026-06-30 |
| 16 | CSS LLC/IL | $893.76K | 0.32% | 2026-06-30 |
| 17 | Walleye Capital LLC | $863.97K | 0.30% | 2026-06-30 |
| 18 | Walleye Trading LLC | $59.58K | 0.02% | 2026-06-30 |
BBIO Insider Trading (Form 4)
Latest: 2026-09-21Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Neil Kumar | Chief Executive Officer | Sell (S) | −10,000 | $69.08 | -$690.8K | EDGAR |
| 2026-08-20 | Neil Kumar | Chief Executive Officer | Sell (S) | −44,980 | $82.86 | -$3.73M | EDGAR |
| 2026-08-18 | Maricel Apuli | Chief Accounting Officer | Tax (F) | −4,714 | $79.86 | -$376.5K | EDGAR |
| 2026-08-18 | Thomas Trimarchi | President and CFO | Tax (F) | −22,781 | $79.86 | -$1.82M | EDGAR |
| 2026-08-18 | Neil Kumar | Chief Executive Officer | Mixed | +34,980 | $79.86 | -$2.89M | EDGAR |
| 2026-08-03 | Maricel Apuli | Chief Accounting Officer | Sell (S) | −2,000 | $80.06 | -$160.1K | EDGAR |
| 2026-07-13 | Andrea Ellis | Director | Mixed | — | $50.38 | -$1.15M | EDGAR |
| 2026-07-13 | Jennifer E. Cook | Director | Mixed | — | $56.75 | -$9.45M | EDGAR |
| 2026-06-24 | James C Momtazee | Director | Award (A) | +3,990 | — | EDGAR | |
| 2026-06-24 | Andrea Ellis | Director | Award (A) | +3,990 | — | EDGAR | |
| 2026-06-24 | Hannah Valantine | Director | Mixed | +1,794 | $58.72 | -$224.3K | EDGAR |
| 2026-06-24 | Fred Hassan | Director | Award (A) | +3,990 | — | EDGAR | |
| 2026-06-24 | Andrew Lo | Director | Award (A) | +3,990 | — | EDGAR | |
| 2026-06-24 | Ali J. Satvat | Director | Award (A) | +3,990 | — | EDGAR | |
| 2026-06-24 | Douglas A. Dachille | Director | Award (A) | +3,990 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
BBIO Insider Holdings
20 insiders · @ $68.15
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | KKR Genetic Disorder L.P. | 10%+ Owner | 19,260,971 | $1.31B | -$1.78B | 1 | 2025-03-07 |
| 2 | Ole Andreas Halvorsen | 10%+ Owner | 18,555,375 | $1.26B | -$2.09B | 2 | 2025-07-01 |
| 3 | KKR & Co. Inc. | 10%+ Owner | 13,260,971 | $903.74M | -$1.44B | 2 | 2025-05-14 |
| 4 | Neil Kumar | Chief Executive Officer | 993,327 | $67.70M | -$149.49M | 79 | 2026-09-21 |
| 5 | Charles J Homcy | Director | 919,876 | $62.69M | -$19.45M | 29 | 2026-06-24 |
| 6 | Frank McCormick | Director | 767,244 | $52.29M | -$33.91M | 16 | 2026-06-24 |
| 7 | Thomas Trimarchi | President and CFO | 336,529 | $22.93M | -$5.99M | 15 | 2026-08-18 |
| 8 | Ali J. Satvat | Director | 169,983 | $11.58M | $0 | 10 | 2026-06-24 |
| 9 | Maricel Apuli | Chief Accounting Officer | 122,687 | $8.36M | -$706.6K | 15 | 2026-08-18 |
| 10 | Brian C Stephenson | CFO and Treasurer | 110,964 | $7.56M | -$9.87M | 45 | 2025-02-27 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
BBIO Board & Officers
As of SEC filings through Sep 21, 2026Directors 13
- Ali J. Satvat · since Jun 27, 2019
- Charles J Homcy · since Jun 27, 2019
- Eric Aguiar · since Jun 27, 2019
- James C Momtazee · since Jun 27, 2019
- Neil Kumar · since Jun 27, 2019
- Jennifer E. Cook · since Dec 12, 2019
- Ronald J Daniels · since Feb 12, 2020
- Andrew Lo · since Jun 23, 2020
- Andrea Ellis · since Aug 17, 2021
- Douglas A. Dachille · since Aug 17, 2021
- Fred Hassan · since Aug 17, 2021
- Hannah Valantine · since Oct 23, 2021
- Frank McCormick · listed since Feb 2023
Officers 3
- Neil Kumar · Chief Executive Officer · listed since Aug 2024
- Thomas Trimarchi · President and CFO · listed since Mar 2025
- Maricel Apuli · Chief Accounting Officer · since Feb 19, 2025
Changes in the last 10 years (91)
| Jun 22, 2026 | The company announced the departure of Randal W. Scott from the board in an SEC filing |
| Jul 1, 2025 | Viking Global Opportunities Portfolio GP LLC reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2025 | Viking Global Opportunities Parent GP LLC reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2025 | Viking Global Opportunities Illiquid Investments Sub-Master LP reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2025 | Viking Global Opportunities GP LLC reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2025 | Viking Global Investors LP reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2025 | Rose Sharon Shabet reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2025 | Ole Andreas Halvorsen reported in an SEC filing no longer being a 10% owner |
| Jul 1, 2025 | David C. Ott reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | KKR Management LLP reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | KKR Group Partnership L.P. reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | KKR Group Holdings Corp. reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | KKR Group Co. Inc. reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | KKR Genetic Disorder L.P. reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | KKR Genetic Disorder GP LLC reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | KKR & Co. Inc. reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | Henry R Kravis reported in an SEC filing no longer being a 10% owner |
| May 14, 2025 | George R Roberts reported in an SEC filing no longer being a 10% owner |
| Mar 21, 2025 | Thomas Trimarchi listed as President and CFO (previously President and COO) in SEC filings |
| Mar 17, 2025 | The company announced the departure of Brian C Stephenson as Secretary, Treasurer & CFO in an SEC filing |
| Feb 19, 2025 | Maricel Apuli became Chief Accounting Officer |
| Sep 17, 2024 | KKR Group Co. Inc. first on file as a 10% owner |
| Aug 20, 2024 | Neil Kumar listed as Chief Executive Officer (previously CEO and President) in SEC filings |
| Jul 23, 2024 | Thomas Trimarchi became President and COO |
| Jul 19, 2023 | Viking Global Opportunities Parent GP LLC first on file as a 10% owner |
| Feb 23, 2023 | Frank McCormick no longer listed as Chairman of Oncology in SEC filings |
| Feb 23, 2023 | Frank McCormick first listed as a director in an SEC filing |
| Feb 21, 2023 | The company announced the departure of Brent L Saunders from the board in an SEC filing |
| Feb 21, 2023 | Richard H Scheller reported in an SEC filing no longer being a director |
| Aug 18, 2022 | Brian C Stephenson listed as Secretary, Treasurer & CFO (previously Title: Secretary, Treasurer and Chief Financial Officer) in SEC filings |
| Dec 6, 2021 | Richard H Scheller no longer listed as Chairman of Research and Development in SEC filings |
| Oct 23, 2021 | Hannah Valantine became a director |
| Aug 17, 2021 | Fred Hassan became a director |
| Aug 17, 2021 | Douglas A. Dachille became a director |
| Aug 17, 2021 | Andrea Ellis became a director |
| Mar 3, 2021 | Charles J Homcy no longer listed as Chairman of Pharmaceuticals in SEC filings |
| Feb 12, 2021 | Brian C Stephenson listed as Title: Secretary, Treasurer and Chief Financial Officer (previously Secretary, Treasurer and Chief Financial Officer) in SEC filings |
| Jan 28, 2021 | Ali J. Satvat no longer listed as a 10% owner in SEC filings |
| Aug 5, 2020 | Brian C Stephenson listed as Secretary, Treasurer and Chief Financial Officer (previously Title: Secretary, Treasurer and Chief Financial Officer) in SEC filings |
| Jun 23, 2020 | Randal W. Scott became a director |
| Jun 23, 2020 | Brent L Saunders became a director |
| Jun 23, 2020 | Andrew Lo became a director |
| Jun 3, 2020 | Brian C Stephenson listed as Title: Secretary, Treasurer and Chief Financial Officer (previously Secretary, Treasurer and Chief Financial Officer) in SEC filings |
| May 21, 2020 | Michael Thomas Henderson listed as Chief Business Officer (previously Senior Vice President, Asset Acquisition, Strategy and Operations) in SEC filings |
| Mar 4, 2020 | Neil Kumar listed as CEO and President (previously Title: Chief Executive Officer and President) in SEC filings |
| Feb 14, 2020 | James C Momtazee no longer listed as a 10% owner in SEC filings |
| Feb 13, 2020 | Neil Kumar listed as Title: Chief Executive Officer and President (previously Chief Executive Officer and President) in SEC filings |
| Feb 12, 2020 | Ronald J Daniels became a director |
| Jan 6, 2020 | Brian C Stephenson listed as Secretary, Treasurer and Chief Financial Officer (previously See Remark) in SEC filings |
| Jan 3, 2020 | KKR Management Holdings L.P. reported in an SEC filing no longer being a 10% owner |
| Jan 3, 2020 | KKR Management Holdings Corp reported in an SEC filing no longer being a 10% owner |
| Jan 1, 2020 | KKR Group Partnership L.P. became a 10% owner |
| Dec 16, 2019 | James C Momtazee first listed as a 10% owner in an SEC filing |
| Dec 16, 2019 | Ali J. Satvat first listed as a 10% owner in an SEC filing |
| Dec 12, 2019 | Jennifer E. Cook became a director |
| Oct 9, 2019 | Yi Ching Yau became Chief Accounting Officer |
| Oct 9, 2019 | Brian M. Stolz became Chief Operating Officer |
| Jun 28, 2019 | Viking Long Fund Master Ltd. first on file as a 10% owner |
| Jun 28, 2019 | Viking Long Fund GP LLC first on file as a 10% owner |
| Jun 28, 2019 | Viking Global Performance LLC first on file as a 10% owner |
| Jun 28, 2019 | Viking Global Equities Master Ltd. first on file as a 10% owner |
| Jun 27, 2019 | Viking Global Opportunities Portfolio GP LLC became a 10% owner |
| Jun 27, 2019 | Viking Global Opportunities Illiquid Investments Sub-Master LP became a 10% owner |
| Jun 27, 2019 | Viking Global Opportunities GP LLC became a 10% owner |
| Jun 27, 2019 | Viking Global Investors LP became a 10% owner |
| Jun 27, 2019 | Uma Sinha became Chief Scientific Officer |
| Jun 27, 2019 | Rose Sharon Shabet became a 10% owner |
| Jun 27, 2019 | Richard H Scheller became a director |
| Jun 27, 2019 | Richard H Scheller became Chairman of Research and Development |
| Jun 27, 2019 | Ole Andreas Halvorsen became a 10% owner |
| Jun 27, 2019 | Neil Kumar became a director |
| Jun 27, 2019 | Neil Kumar became Chief Executive Officer and President |
| Jun 27, 2019 | Michael Thomas Henderson became Senior Vice President, Asset Acquisition, Strategy and Operations |
| Jun 27, 2019 | KKR Management LLP became a 10% owner |
| Jun 27, 2019 | KKR Management Holdings L.P. became a 10% owner |
| Jun 27, 2019 | KKR Management Holdings Corp became a 10% owner |
| Jun 27, 2019 | KKR Group Holdings Corp. became a 10% owner |
| Jun 27, 2019 | KKR Genetic Disorder L.P. became a 10% owner |
| Jun 27, 2019 | KKR Genetic Disorder GP LLC became a 10% owner |
| Jun 27, 2019 | KKR & Co. Inc. became a 10% owner |
| Jun 27, 2019 | James C Momtazee became a director |
| Jun 27, 2019 | Henry R Kravis became a 10% owner |
| Jun 27, 2019 | George R Roberts became a 10% owner |
| Jun 27, 2019 | Frank McCormick became Chairman of Oncology |
| Jun 27, 2019 | Eric Aguiar became a director |
| Jun 27, 2019 | David C. Ott became a 10% owner |
| Jun 27, 2019 | Charles J Homcy became a director |
| Jun 27, 2019 | Charles J Homcy became Chairman of Pharmaceuticals |
| Jun 27, 2019 | Cameron Turtle became Senior Vice President, Portfolio Management and Corporate Development |
| Jun 27, 2019 | Brian C Stephenson became See Remark |
| Jun 27, 2019 | Ali J. Satvat became a director |
Not reported recently (9)
- Cameron Turtle · Last reported as Senior Vice President, Portfolio Management and Corporate Development in an SEC filing dated Dec 29, 2020
- Uma Sinha · Last reported as Chief Scientific Officer in an SEC filing dated Dec 17, 2020
- Michael Thomas Henderson · Last reported as Chief Business Officer in an SEC filing dated Dec 17, 2020
- Yi Ching Yau · Last reported as Chief Accounting Officer in an SEC filing dated Nov 18, 2020
- Brian M. Stolz · Last reported as Chief Operating Officer in an SEC filing dated Aug 18, 2020
- Viking Long Fund Master Ltd. · Last reported as a 10% owner in an SEC filing dated Jun 28, 2019
- Viking Long Fund GP LLC · Last reported as a 10% owner in an SEC filing dated Jun 28, 2019
- Viking Global Equities Master Ltd. · Last reported as a 10% owner in an SEC filing dated Jun 28, 2019
- Viking Global Performance LLC · Last reported as a 10% owner in an SEC filing dated Jun 28, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
BBIO Proposed Insider Sales (Form 144)
Latest: 2026-08-19
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
3 filings
· $7.0M notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
NEIL KUMAR (2, $5.3M) · RANDAL SCOTT (1, $1.7M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019 | Director, Officer | 30,000 | $2.49M | 2026-08-19 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-18 | NEIL KUMAR | Director, Officer | 34,980 | $2.79M | 2026-08-18 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-17 | RANDAL SCOTT | Director | 21,501 | $1.72M | 2026-08-17 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-09 | JENNIFER COOK | Director | 148,589 | $13.16M | 2026-07-09 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-09 | ANDREA ELLIS | Director | 17,167 | $1.44M | 2026-07-09 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-24 | RANDAL SCOTT | Director | 2,196 | $150.7K | 2026-06-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-24 | JENNIFER COOK | Director | 37,167 | $2.60M | 2026-06-24 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | JENNIFER COOK | Director | 2,196 | $150.6K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-23 | HANNAH A VALANTINE | Director | 2,196 | $150.6K | 2026-06-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-22 | HANNAH A VALANTINE | Director | 2,808 | $190.9K | 2026-06-22 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
107 ETFs hold BBIO
25 shown · $1.54B total exposure · 0.12% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.02% | $369.6M | — | 2026-09-30 |
| 2 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.15% | $260.6M | — | 2026-09-30 |
| 3 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.33% | $144.9M | — | 2026-09-30 |
| 4 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.36% | $141.3M | $10.4B | 2026-10-23 |
| 5 | VXF Vanguard Extended Market ETF | Vanguard | 0.14% | $129.0M | — | 2026-09-30 |
| 6 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.85% | $91.4M | $10.7B | 2026-10-23 |
| 7 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.33% | $61.7M | $18.9B | 2026-10-23 |
| 8 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.24% | $54.0M | — | 2026-05-31 |
| 9 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.09% | $48.6M | $57.3B | 2026-10-23 |
| 10 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.03% | $41.2M | $123.5B | 2026-10-23 |
| 11 | VHT Vanguard Health Care ETF | Vanguard | 0.14% | $30.5M | — | 2026-09-30 |
| 12 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.21% | $30.4M | — | 2026-05-31 |
| 13 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.03% | $17.2M | — | 2026-09-30 |
| 14 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.02% | $15.6M | $96.5B | 2026-10-23 |
| 15 | PSC Principal U.S. Small-Cap ETF | Nport | 0.60% | $14.1M | — | 2026-06-30 |
| 16 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.33% | $13.8M | $4.2B | 2026-10-23 |
| 17 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 0.96% | $10.9M | $1.1B | 2026-10-23 |
| 18 | VT Vanguard Total World Stock ETF | Vanguard | 0.01% | $9.5M | — | 2026-09-30 |
| 19 | FPX First Trust US Equity Opportunities ETF | First Trust | 0.62% | $8.5M | $1.4B | 2026-10-23 |
| 20 | JGRO JPMorgan Active Growth ETF | JPMorgan | 0.08% | $8.3M | $9.7B | 2026-10-26 |
| 21 | QQQJ Invesco NASDAQ Next Gen 100 ETF | Invesco | 0.69% | $8.2M | — | 2026-10-24 |
| 22 | IWB iShares Russell 1000 ETF | iShares (BlackRock) | 0.02% | $8.0M | $48.7B | 2026-10-23 |
| 23 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.01% | $7.9M | — | 2026-10-23 |
| 24 | IYH iShares U.S. Healthcare ETF | iShares (BlackRock) | 0.17% | $7.8M | $4.5B | 2026-10-23 |
| 25 | SMMD iShares Russell 2500 ETF | iShares (BlackRock) | 0.16% | $6.7M | $4.1B | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-3.57
TTM Revenue
$713.07M
TTM Net Income
$-691.87M
TTM Op. Cash Flow
$-434.37M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $243.68M | $-152.22M | $-0.78 | $-71.10M |
| Q1 '26 | 2026-03-31 | $194.51M | $-164.04M | $-0.84 | $-197.28M |
| Q4 '25 | 2025-12-31 | $154.18M | $-192.86M | $-0.99 | $-56.42M |
| Q3 '25 | 2025-09-30 | $120.70M | $-182.74M | $-0.95 | $-109.57M |
| Q2 '25 | 2025-06-30 | $110.56M | $-181.90M | $-0.95 | $-80.68M |
| Q1 '25 | 2025-03-31 | $116.63M | $-167.42M | $-0.88 | $-199.24M |
| Q4 '24 | 2024-12-31 | $5.88M | $-265.05M | $-1.42 | $-195.33M |
| Q3 '24 | 2024-09-30 | $2.73M | $-162.04M | $-0.86 | $-180.57M |
| Q2 '24 | 2024-06-30 | $2.17M | $-73.46M | $-0.39 | $74.70M |
| Q1 '24 | 2024-03-31 | $211.12M | $-35.22M | $-0.20 | $-219.54M |
| Q4 '23 | 2023-12-31 | $1.75M | $-168.15M | $-0.96 | $-124.82M |
| Q3 '23 | 2023-09-30 | $4.09M | $-177.00M | $-1.08 | $-145.23M |
Q2 2026 • period ending 2026-06-30 • filed 2026-08-10
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
—
P/S
18.54
EV/EBITDA
—
EV/Sales
20.29
ROE
—
ROA
-56.8%
Div Yield
0.00%
FCF Yield
-3.29%
Debt/Equity
—
Current Ratio
—
Market Cap
$13.22B
as of 2026-10-26
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
19.67M
SI % of Float
12.27%
Days to Cover
5.85
Short Vol Ratio
48.3%
Free Float
160.36M
Float %
82.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-24